DEFA14A: Trevi Therapeutics Sets Date for 2025 Annual Meeting, Outlines Key Proposals for Stockholder Vote

Trevi Therapeutics has scheduled its 2025 Annual Meeting for June 11, 2025, and is seeking stockholder votes on director elections, auditor ratification, executive compensation, and an amendment to the stock incentive plan.

Summary

• Trevi Therapeutics is holding its Annual Meeting of Stockholders on June 11, 2025.
• Stockholders are being asked to vote on several key proposals.
• These proposals include the election of two Class III directors, Jennifer Good and Anne VanLent, to serve until the 2028 Annual Meeting.
• Another proposal is the ratification of Ernst & Young LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2025.
• Stockholders will also vote on an advisory basis regarding the compensation paid to the company's named executive officers and the frequency of future advisory votes on executive compensation.
• Additionally, there is a proposal to amend the Trevi Therapeutics, Inc. 2019 Stock Incentive Plan to increase the number of shares available for issuance by 6,000,000 shares.
• Stockholders can vote in advance of the meeting until June 10, 2025, or virtually during the meeting.
• Proxy materials, including the Notice, Proxy Statement, and Form 10-K, are available online.

Sentiment

Score: 7

Explanation: The document is a standard proxy statement, which is generally neutral in tone. The proposals are typical for a public company, and the information is presented in a clear and organized manner.

Positives

• The company is providing stockholders with multiple avenues to access proxy materials and vote, including online, phone, and email.
• The proposals are clearly outlined, allowing stockholders to make informed decisions.

Future Outlook

The document outlines the matters to be voted on at the upcoming annual meeting, which will influence the company's governance and executive compensation structure.

Industry Context

Proxy statements are a standard part of corporate governance, providing transparency and allowing shareholders to participate in key decisions. The proposals outlined are typical for a company seeking to maintain operational flexibility and align executive incentives with shareholder value.

Stakeholder Impact

• Shareholders have the opportunity to influence the company's direction through their votes.
• Employees may be affected by the approval of the stock incentive plan amendment.
• The outcome of the votes could impact the company's financial performance and strategic direction.

Next Steps

• Stockholders should review the proxy materials and vote on the proposals before the deadline.
• The company will hold its Annual Meeting on June 11, 2025, to discuss and vote on the proposals.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Executive Compensation, Stock Incentive Plan, Ernst & Young, Shares, Vote, Trevi Therapeutics